DK1313762T3 - Suppressor-gen - Google Patents

Suppressor-gen

Info

Publication number
DK1313762T3
DK1313762T3 DK01954168T DK01954168T DK1313762T3 DK 1313762 T3 DK1313762 T3 DK 1313762T3 DK 01954168 T DK01954168 T DK 01954168T DK 01954168 T DK01954168 T DK 01954168T DK 1313762 T3 DK1313762 T3 DK 1313762T3
Authority
DK
Denmark
Prior art keywords
suppressor gene
modulating
activity
tumour suppressor
polypeptides capable
Prior art date
Application number
DK01954168T
Other languages
Danish (da)
English (en)
Inventor
Xin Lu
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0019018A external-priority patent/GB0019018D0/en
Priority claimed from GB0029996A external-priority patent/GB0029996D0/en
Priority claimed from GB0112890A external-priority patent/GB0112890D0/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of DK1313762T3 publication Critical patent/DK1313762T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Audible-Bandwidth Dynamoelectric Transducers Other Than Pickups (AREA)
  • Bipolar Transistors (AREA)
DK01954168T 2000-08-04 2001-08-06 Suppressor-gen DK1313762T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0019018A GB0019018D0 (en) 2000-08-04 2000-08-04 Suppressor gene
GB0029996A GB0029996D0 (en) 2000-12-08 2000-12-08 Suppressor gene
GB0112890A GB0112890D0 (en) 2001-05-26 2001-05-26 Suppressor Gene

Publications (1)

Publication Number Publication Date
DK1313762T3 true DK1313762T3 (da) 2006-10-30

Family

ID=27255828

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01954168T DK1313762T3 (da) 2000-08-04 2001-08-06 Suppressor-gen

Country Status (14)

Country Link
US (1) US20040053262A1 (xx)
EP (2) EP1313762B1 (xx)
JP (1) JP2004525605A (xx)
CN (1) CN1310942C (xx)
AT (1) ATE332309T1 (xx)
AU (2) AU2001276515B2 (xx)
CA (1) CA2417368A1 (xx)
CY (1) CY1106187T1 (xx)
DE (1) DE60121346T8 (xx)
DK (1) DK1313762T3 (xx)
ES (1) ES2269430T3 (xx)
HK (1) HK1057377A1 (xx)
PT (1) PT1313762E (xx)
WO (1) WO2002012325A2 (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852108B2 (en) 2002-05-14 2005-02-08 Spiration, Inc. Apparatus and method for resecting and removing selected body tissue from a site inside a patient
EP1947113B1 (en) 2002-10-07 2011-12-14 Ludwig Institute for Cancer Research Ltd P53 binding polypeptide
GB0223187D0 (en) * 2002-10-07 2002-11-13 Ludwig Inst Cancer Res Screen
EP1690094A1 (en) * 2003-12-04 2006-08-16 Ludwig Institute For Cancer Research Screening assay and treatment
EP1697751A2 (en) * 2003-12-04 2006-09-06 Ludwig Institute For Cancer Research Assay and treatment
GB0328690D0 (en) 2003-12-10 2004-01-14 Ludwig Inst Cancer Res Tumour suppressor protein
WO2005093098A1 (en) * 2004-03-12 2005-10-06 Ludwig Institute For Cancer Research Differential drug sensitivity
AU2005314089B2 (en) * 2004-12-08 2011-03-03 Cedars-Sinai Medical Center Methods for diagnosis and treatment of Crohn's disease
PL1838350T3 (pl) 2005-01-20 2015-02-27 Ryboquin Company Ltd Modulatory aktywności ubikwitynazy itch
WO2008045344A2 (en) * 2006-10-06 2008-04-17 The General Hospital Corporation Methods to determine responsiveness to cisplatin treatment
US20100021917A1 (en) * 2007-02-14 2010-01-28 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
US20100184050A1 (en) * 2007-04-26 2010-07-22 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
US8853180B2 (en) * 2009-09-10 2014-10-07 Mayo Foundation For Medical Education And Research Methods and materials for modulating deubiquitinases and ubiquitinated polypeptides
US9880171B2 (en) 2012-03-02 2018-01-30 Ludwig Institute For Cancer Research Ltd. iASPP phosphorylation and metastatic potential
WO2014160883A1 (en) 2013-03-27 2014-10-02 Cedars-Sinai Medical Center Treating fibrosis and inflammation by inhibiting tl1a
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
CN116083547A (zh) 2015-11-19 2023-05-09 赛纳生物科技(北京)有限公司 一种校正测序期间超前量的方法
CN106874709B (zh) * 2015-12-12 2019-03-01 北京大学 测序结果中序列数据错误的检测和校正方法
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5977311A (en) * 1997-09-23 1999-11-02 Curagen Corporation 53BP2 complexes
EP1117791A2 (en) * 1998-10-05 2001-07-25 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
US7141384B1 (en) * 1998-10-06 2006-11-28 Georgetown University Detection of pleiotrophin
EP1146054A4 (en) * 1998-12-03 2003-08-06 Ono Pharmaceutical Co RE1A BINDING INHIBITOR, METHOD FOR THE PRODUCTION THEREOF, AND USE OF SAID BINDING INHIBITOR
CA2402563A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1572987A4 (en) * 2000-02-03 2005-11-30 Nuvelo Inc NUCLEIC ACIDS AND POLYPEPTIDES

Also Published As

Publication number Publication date
DE60121346T2 (de) 2007-07-19
JP2004525605A (ja) 2004-08-26
EP1710582A3 (en) 2006-11-02
DE60121346T8 (de) 2007-12-13
US20040053262A1 (en) 2004-03-18
ES2269430T3 (es) 2007-04-01
CN1446228A (zh) 2003-10-01
HK1057377A1 (en) 2004-04-02
EP1313762A2 (en) 2003-05-28
PT1313762E (pt) 2006-11-30
DE60121346D1 (en) 2006-08-17
EP1313762B1 (en) 2006-07-05
AU7651501A (en) 2002-02-18
CY1106187T1 (el) 2011-06-08
WO2002012325A2 (en) 2002-02-14
ATE332309T1 (de) 2006-07-15
CA2417368A1 (en) 2002-02-14
WO2002012325A3 (en) 2003-03-06
CN1310942C (zh) 2007-04-18
EP1710582A2 (en) 2006-10-11
AU2001276515B2 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
ATE332309T1 (de) Suppressor-gen
DE69838249D1 (de) Anti-apo-2 antikörper
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
DE69432031D1 (de) Huntingtin-DNA, Protein und Verwendung
DE69841307D1 (de) Verwendung von peroxiden zur bekämpfung der haarigen warzenerkrankung
PT797676E (pt) Vector adenoviral recombinante e metodos de utilizacao
DK1521831T3 (da) Transgent dyr der udtrykker trunkeret alzheimers tauprotein
ATE310085T1 (de) Cyclin-e2 proteine und dafür kodierende gene
DE69424209T2 (de) Tumorsuppressor-Gen Merlin und dessen Verwendungen
PT816504E (pt) Acetil-hidrolase para o factor activador das plaquetas, e seu gene
EA199900794A1 (ru) Cash (гомолог каспазы) с "гибель-эффекторным" доменом, модуляторы функций fas-рецепторов
ATE368733T1 (de) Bfit (brown fat inducible thioesterase) polypeptide und polynukleotide und ihre verwendung
WO2002093127A3 (en) Methods and reagents for identifying insulin response modulators and therapeutic uses therefor
ATE344802T1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
WO2003087832A3 (en) Diagnosis of carcinoma using raigi polypeptides
ATE386803T1 (de) Intrazelluläre glukocortikoid-induzierte leucin- zipper modulatoren von mechanismen des apoptotischen zelltodes
WO2002077190A8 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2001066745A3 (en) Presenilin/crk binding polypeptides (pcbp) and methods of use thereof
ATE257862T1 (de) Verwendung von calculus
WO2002077220A3 (en) Nucleic acids encoding human est1 proteins
WO2002077193A8 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof